Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: A 2-year randomized, treat-to-target trial

Diabetic Medicine

Volumn 30, Issue 11, 2013, Pages 1298-1304

  Rodbard, H W ^a   Cariou, B ^b   Zinman, B ^c   Handelsman, Y ^d   Philis Tsimikas, A ^e   Skjoth T V ^f   Rana, A ^f   Mathieu, C ^g  

^a Endocrine and Metabolic Consultants   (United States)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c MOUNT SINAI HOSPITAL   (Canada)

^d Metabolic Institute of America   (United States)

^e Whittier Institute for Diabetes   (United States)

^f NOVO NORDISK A S   (Denmark)

^g UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE; HEMOGLOBIN A1C; INSULIN DEGLUDEC; INSULIN GLARGINE; METFORMIN;

ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HEART ARREST; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RISK REDUCTION; SIDE EFFECT; TREATMENT DURATION; WEIGHT GAIN;

ADMINISTRATION, ORAL; ANALYSIS OF VARIANCE; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; TREATMENT OUTCOME;

EID: 84885946179     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12303     Document Type: Article

References (8)

1. Jonassen I, Havelund S, Hoeg-Jensen T, Steensgaard DB, Wahlund PO, Ribel U. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res 2012; 29: 2104-2114.
2. Zinman B, Philis-Tsimikas A, Cariou B, Handelsman Y, Rodbard HW, Johansen T, et al. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care 2012; 35: 2464-2471.
3. Declaration of Helsinki. Ethical principles for medical research involving human subjects. J Indian Med Assoc 2009; 107: 403-405.
4. ICH Harmonised Tripartite Guideline. Guideline for good clinical practice. J Postgrad Med 2001; 47: 199-203.
5. Heise T, Nosek L, Bottcher SG, Hastrup H, Haahr H. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab 2012; 14: 944-950.
6. Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab 2012; 14: 859-864.
7. Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes. Diabetologia 2002; 45: 937-948.
8. Jabbour S. Primary care physicians and insulin initiation: multiple barriers, lack of knowledge or both? Int J Clin Pract 2008; 62: 845-847.